Medline Industries, Inc., a leading global manufacturer and distributor of healthcare supplies, is headquartered in the United States. Founded in 1910, the company has established a strong presence in North America and beyond, serving hospitals, nursing homes, and other healthcare facilities. Medline is renowned for its extensive range of products, including surgical instruments, medical apparel, and infection prevention solutions, all designed to enhance patient care and operational efficiency. With a commitment to innovation, Medline has achieved significant milestones, such as expanding its product lines and investing in advanced manufacturing technologies. The company holds a prominent market position, recognised for its quality and reliability, making it a trusted partner in the healthcare industry. Medline's dedication to customer service and tailored solutions further distinguishes it in a competitive landscape.
How does Medline Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medline Industries's score of 38 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Medline Industries reported total carbon emissions of approximately 320,260 kg CO2e from Scope 3 upstream transport and distribution activities in the UK. Additionally, Scope 2 emissions were recorded at about 11,850 kg CO2e, while Scope 1 emissions were negligible at 0 kg CO2e. This reflects a significant reduction from 2023, where total emissions were approximately 484,250 kg CO2e, comprising 1,330 kg CO2e from Scope 1, 11,310 kg CO2e from Scope 2, and a substantial 471,610 kg CO2e from Scope 3. Medline Industries has set ambitious climate commitments, aiming for a 30% reduction in both Scope 1 and Scope 2 emissions from a 2023 baseline by 2030. Furthermore, the company is committed to achieving Net Zero emissions by 2050, with projections indicating a 42% reduction in total Scope 1 and Scope 2 emissions by 2030, targeting a reduction to 63 kg CO2e. For Scope 3 emissions, limited to five sub-categories required by the NHS, a 25% reduction is projected, aiming for 513 kg CO2e by 2030. These commitments are part of Medline's broader strategy to enhance sustainability and reduce its carbon footprint, aligning with industry standards and climate action goals. The data reflects a proactive approach to managing emissions and contributing to global climate initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2019 | 2020 | 2021 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 45,201,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 81,309,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | 90,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medline Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
